🏛️ Verified NIH Record • Updated 2025-10-13
Nasal Antisepsis for C. Auris Prevention (NCT06282510)
Impact of Nasal Antisepsis on Candida Auris Colonization
🟢 Recruiting Phase4 💊 Investigational Drug / Biologic Sponsor: Mary K Hayden
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, controlled, open-label trial of effect of 10% povidone iodine intranasal antisepsis on the detection of Candida auris.
Who can join: Review the eligibility criteria below.
Location: Rush University Medical Center — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Rush University Medical Center — Chicago, Illinois
- RML Specialty Hospital — Chicago, Illinois
- RML Specialty Hospital — Hinsdale, Illinois
📞 Contact the Study Coordinator
Phone: (312) 563-6201
Email: sarah_e_sansom@rush.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Candida Auris Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.